Drugs / HS-10356
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04652297 | Dec 2020 → Aug 2021 | — | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04652297 ↗ |
| Route | Oral | “daily oral doses of 6,15,30mg HS-10356, QD” NCT04652297 ↗ |